IM-250 is an anti-herpetic drug candidate[1] developed by Innovative Molecules Gmbh.[2] The drug was conceived by a chemist at the company, who hypothesized that swapping the sulfonamide function group on pritelivir for a sulfoximine would reduce off-target effects. Chemists at the company also tweaked an aromatic group on pritelivir to make their drug candidate more likely to enter the central nervous system, where it could go after latent HSV.[3]
| |
| Names | |
|---|---|
| IUPAC name
(S)-2-[4-(2,5-difluorophenyl)phenyl]-N-methyl-N-[4-methyl-5-(methylsulfonimidoyl)-1,3-thiazol-2-yl]acetamide
| |
| Identifiers | |
3D model (JSmol)
|
|
PubChem CID
|
|
| |
| |
| Properties | |
| C20H19F2N3O2S2 | |
| Molar mass | 435.51 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Innovative Molecules is trying to raise 20 million euro for a clinical trial on humans.[4]
See also
editReferences
edit- ^ Gege, Christian; Bravo, Fernando J.; Uhlig, Nadja; Hagmaier, Timo; Schmachtenberg, Rosanne; Elis, Julia; Burger-Kentischer, Anke; Finkelmeier, Doris; Hamprecht, Klaus; Grunwald, Thomas; Bernstein, David I.; Kleymann, Gerald (16 June 2021). "A helicase-primase drug candidate with sufficient target tissue exposure affects latent neural herpes simplex virus infections". Science Translational Medicine. 13 (598). doi:10.1126/scitranslmed.abf8668. PMID 34135112.
- ^ "Drug Candidate Shows 'Potent Anti-Herpes Activity'". 17 June 2021.
- ^ "Small molecule fights active and latent herpes infections in rodents".
- ^ Lücking, Ulrich (7 October 2022). "New Opportunities for the Utilization of the Sulfoximine Group in Medicinal Chemistry from the Drug Designer's Perspective". Chemistry – A European Journal. 28 (56): e202201993. doi:10.1002/chem.202201993. PMID 35789054.
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |